ClinicalTrials.Veeva

Menu
O

Olympian Clinical Research | Tampa, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
Lebrikizumab
Rapastinel
Ixekizumab
Guselkumab
CP-690,550
Dupilumab
PF-06700841
RO7790121
Tulisokibart

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 56 total trials

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accept...

Active, not recruiting
Generalized Anxiety Disorder
Drug: Placebo
Drug: SEP-363856

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Active, not recruiting
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling
Chronic Spontaneous Urticaria
Biological: Matching placebo
Biological: barzolvolimab

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic...

Enrolling
Atopic Dermatitis
Drug: Afimkibart
Drug: Placebo

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Active, not recruiting
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib

The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or...

Active, not recruiting
Hidradenitis Suppurativa
Drug: secukinumab

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to sev...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Tulisokibart

Trial sponsors

Lilly logo
Pfizer logo
Incyte logo
Allergan logo
Janssen (J&J Innovative Medicine) logo
Biohaven logo
LEO Pharma logo
Novartis logo
Otsuka logo
Roche logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems